Table 1. Demographic parameters of all virus-associated anterior uveitis cohorts.
| P Value | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | CMV | HSV | VZV | RV | MV | CMV vs HSV | CMV vs VZV | CMV vs RV | CMV vs MV | HSV vs VZV | HSV vs RV | HSV vs MV | VZV vs RV | VZV vs MV | RV vs. MV | ||
| Number of patients (%) | 270 | 57 (21) | 77 (29) | 45 (17) | 77 (29) | 14 (5) | |||||||||||
| Median age at presentation (range) | 52 (19–96) | 42 (19–89) | 56 (19–87) | 67 (19–96) | 44 (19–76) | 75 (28–81) | <0.0001 | 0.0022 | 0.0018 | 0.7373 | 0.0021 | 0.3242 | 0.0004 | 0.1183 | 0.0004 | 0.3465 | 0.0004 |
| Gender | |||||||||||||||||
| Female (%) | 120 (44) | 21 (37) | 40 (52) | 25 (56) | 30 (39) | 4 (29) | 0.1029 | 0.0826 | 0.0593 | 0.8028 | 0.5616 | 0.3853 | 0.1056 | 0.1074 | 0.0755 | 0.0778 | 0.4598 |
| Male (%) | 150 (56) | 36 (63) | 37 (48) | 20 (44) | 47 (61) | 10 (71) | |||||||||||
| Median of Antibody-Index (GWC) (range) | 5.6 (1.31–485.5) | 7.265 (1.6–485.5) | 5.495 (2.1–109.7) | 4.330 (1.31–106.6) | 6.450 (1.89–199.7) | 3.94 (1.91–83.33) | 0.0038 | 0.0423 | 0.0047 | 0.6101 | 0.0021 | 0.1842 | 0.0972 | 0.0708 | 0.0059 | 0.6107 | 0.0028 |
| Unilateral | 230 (85) | 56 (98) | 66 (86) | 34 (76) | 62 (81) | 12 (86) | 0.0149 | 0.012 | 0.0004 | 0.0018 | 0.0368 | 0.1591 | 0.3895 | >0.999 | 0.5183 | 0.4232 | 0.6464 |
| Bilateral | 40 (15) | 1 (2) | 11 (14) | 11 (24) | 15 (19) | 2 (14) | |||||||||||
| Acute course | 123 (46) | 55 (96) | 25 (32) | 23 (55) | 10 (16) | 7 (50) | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | 0.042 | 0.0274 | 0.2063 | <0.0001 | 0.9421 | 0.006 |
| Chronic course | 147 (54) | 2 (4) | 52 (68) | 22 (49) | 52 (84) | 7 (50) | |||||||||||
| Previous keratitis | 150 (56) | 0 (0) | 44 (57) | 23 (51) | 25 (40) | 6 (43) | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | 0.5183 | 0.0487 | 0.320 | 0.268 | 0.5895 | 0.816 |
| Visual acuity median in logMAR (range) | 0.2 (0–2.5) | 0 (0–2) | 0.2 (-0.1–2.5) | 0.5 (0–2.5) | 0.2 (0–2.5) | 0.3 (0–1) | <0.0001 | 0.0028 | <0.0001 | 0.0020 | 0.0035 | 0.0028 | 0.8261 | 0.5886 | 0.0003 | 0.0520 | 0.3528 |
| Intra ocular pressure (IOP) median in mmHG (range) | 18 (6–58) | 27 (10–55) | 16 (6–38) | 18 (7–40) | 16 (8–58) | 16.5 (8–42) | <0.0001 | <0.0001 | 0.0009 | <0.0001 | 0.0163 | 0.1116 | 0.8376 | 0.7248 | 0.1571 | 0.7274 | 0.7913 |
| IOP | |||||||||||||||||
| >21–29 mmHg | 81 (30) | 27 (47) | 15 (19) | 14 (31) | 22 (29) | 3 (21) | <0.0001 | 0.0002 | 0.2419 | 0.0007 | 0.4906 | 0.0099 | 0.7416 | 0.0037 | 0.0339 | 0.0632 | 0.0104 |
| Acute course | 48 (59) | 27 (100) | 8 (53) | 6 (43) | 5 (23) | 2 (67) | |||||||||||
| Chronic course | 33 (41) | 0 (0) | 7 (47) | 8 (57) | 17 (77) | 1 (33) | |||||||||||
| IOP | |||||||||||||||||
| >30 mmHg | 39 (14) | 19 (33) | 3 (4) | 8 (18) | 6 (8) | 3 (21) | 0.3718 | 0.1487 | 0.3486 | 0.4373 | 0.9286 | 0.1394 | 0.5 | 0.2 | 0.7299 | 0.2606 | 0.2976 |
| Acute course | 25 (64) | 19 (100) | 1 (33) | 3 (38) | 0 (0) | 2 (67) | |||||||||||
| Chronic course | 14 (36) | 0 (0) | 2 (67) | 5 (62) | 6 (100) | 1 (33) | |||||||||||
| Number of local antiglaucomatous eye drops | <0.0001 | <0.0001 | <0.0001 | <0.0001 | 0.1487 | 0.2645 | 0.3967 | 0.6740 | 0.2628 | 0.042 | 0.3138 | ||||||
| 0 | 125 | 10 | 38 | 27 | 45 | 5 | |||||||||||
| 1 | 50 | 5 | 16 | 10 | 16 | 3 | |||||||||||
| 2 | 61 | 21 | 18 | 8 | 10 | 4 | |||||||||||
| 3 | 34 | 21 | 5 | 0 | 6 | 2 | |||||||||||
| Systemic acetazolamide | |||||||||||||||||
| yes | 222 (82) | 34 (60) | 69 (90) | 35 (78) | 71 (82) | 10 (71) | <0.0001 | <0.0001 | 0.052 | <0.0001 | 0.4159 | 0.0754 | 0.5606 | 0.0644 | 0.0227 | 0.6258 | 0.0222 |
| no | 48 (18) | 23 (40) | 8 (10) | 10 (22) | 6 (8) | 4 (29) | |||||||||||
CMV = cytomegalovirus, GWC = Goldmann–Witmer coefficient, HSV = herpes simplex virus, IOP = Intraocular pressure, logMAR = log of the Minimum Angle, MV = multiple virus, RV = rubella virus, VZV = varicella-zoster virus
Kruskal-Wallis test, Chi-square-Test, Mann-Whitney Test were performed.